Novartis Reports the Results for Scemblix (asciminib) in P-III Clinical Trial for the Treatment of Newly Diagnosed Chronic Myeloid Leukemia
Shots:
- The P-III (ASC4FIRST) trial evaluates Scemblix (80mg, QD) vs SoC TKI (imatinib/nilotinib/dasatinib/bosutinib) in patients (n=405) with Ph+ CML-CP. 1EP includes safety & efficacy of Scemblix vs Soc TKI or TKI within the stratum of participants & 2EPs includes MMR, MR4, MR4.5, CHR, duration of & time to first MMR, MR4 & MR4.5 along with EFS, FFS, PFS & OS
- The study met both the 1EPs & depicted clinically meaningful & statistically significant results & for 2EPs, superior MMR rates at wk48 vs. SoC TKIs were seen. Regulatory filings & presentations expected in 2024
- Scemblix is a TKI that functions by specifically targeting the ABL myristoyl pocket that has been approved in 60 countries incl. the US & EU for Ph+ CML-CP
Ref: Novartis | Image: Novartis
Related News:- Novartis’ Scemblix (asciminib) Receives EC’s Approval for the Treatment of Chronic Myeloid Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
